Verified Rigor RecordRigor Reviewed

Rigor-Reviewed Manuscript

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.

Name: Verified Rigor Record — Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.
Item: Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.
Rating: 96
Author: Αlpha¹

Cho BC, Balaraman R, Chen HJ, Yu X, Fawole A, Liu ZG, Zhang J, Wu L, Yang B, Leddon JL, Hamm J, Huang Y, Wu L, Pan P, Singh P, Beardsley A, Kayali F, Davarifar A, Lee KH, Park KU, Lee Y, Li L, Wang X, Sun M, Yu Y, Jain V, Shpyro S, Wang Q, Wenger M, Şahin U, Efuni S, Song S, He K, Zheng P, Liu Y, He K, Li T, Socinski MA, Wu YL

Paper source

Open DOI

Embed this Rigor badge

Αlpha¹ Verified Rigor Record — Rigor score 96/100 (Exceptional strength of evidence) for “Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.”

Links back to this verified record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · July 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

PASS

Rigor holds up · Interventional Study

Eight dimensions — click a segment for details

Critical

High-priority

Model-reported confidence: highReviewer agreement: moderateEngine: 7.7.0Source: full text

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is methodologically sound for a nonpivotal stage 1 report, with strong ethics reporting, biological variables, and analysis reproducibility. Weaknesses include missing justification for the open-label design, incomplete identification of the comparator source, and lack of explicit assumption verification in the statistical analysis. Two claims in the abstract/discussion are overstated relative to the evidence.

Three independent reviewers evaluated all eight dimensions; the synthesis weighted specific verifiable evidence (e.g., missing manufacturer, missing outlier handling) over general impressions. The statistics verification component checked 1 test (consistent); many analyses (e.g., secondary endpoints, subgroup tests) were not verified. The citation check found one reference not located in any registry. The claim audit identified two overstated conclusions.

10 major claims checked against the paper's own evidence: 2 not fully backed by the presented evidence (unsupported or overstated).

Recomputed 1 test: 1 consistent, 0 inconsistent, 1 via agent-written checks.

Rigor

Eight Dimensions7 pass · 1 warn

10 major claims2 overstated1 partial7 supported

The introduction cites prior research establishing the poor prognosis of patients with PD-(L)1-resistant sqNSCLC and the modest efficacy of docetaxel. It provides a logical rationale linking the pH-sensitive mechanism of gotistobart to improved Treg depletion and antitumor activity, supported by preclinical and early clinical data from PRESERVE-001. The paper acknowledges limitations of prior work, such as the failure of multiple other agents to show an OS benefit over docetaxel in this setting.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a clear scientific premise by citing prior work on the poor prognosis of the target population, the mechanism of gotistobart, and the results from the phase 1/2 PRESERVE-001 study.

Evidence

direct quote[Introduction, paragraph 1]

“Docetaxel has modest efficacy, as patients with PD-(L)1-resistant sqNSCLC have a median survival ranging from 8.0 to 9.4 months, and treatment is associated with considerable toxicity.”

direct quote[Introduction, paragraph 2]

“Unlike other clinically used anti-CTLA-4 antibodies, the acidic pH-sensitive mechanism of action of gotistobart avoids lysosomal degradation of both CTLA-4 and the anti-CTLA-4 antibody and thus preserves both the CTLA-4 molecules and the antibody.”

direct quote[Discussion, paragraph 3]

“Multiple studies assessing novel therapeutic approaches in the post-platinum, post-PD-(L)1 inhibitor setting have failed to demonstrate an OS benefit over docetaxel, including...”

PASSReviewer 2· 95% conf

The paper extensively cites prior research on NSCLC, PD-(L)1 resistance, and the novel mechanism of gotistobart, establishing a clear rationale for the study.

Evidence

direct quote[Introduction, paragraphs 1-3]

“These patients represent a lung cancer population with substantial unmet need. Gotistobart (BNT316/ONC-392) is a novel tumor microenvironment-selective regulatory T cell (T reg ) depletion antibody targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4) .”

direct quote[Discussion, paragraph 3]

“Multiple studies assessing novel therapeutic approaches in the post-platinum, post-PD-(L)1 inhibitor setting have failed to demonstrate an OS benefit over docetaxel...”

direct quote[Introduction, last paragraph]

“Stage 1 is exploratory and was not powered to demonstrate efficacy.”

PASSReviewer 3· 95% conf

The scientific premise is well-established by citing the unmet need in sqNSCLC, prior data on gotistobart from phase 1/2, and the failures of other therapies. The rationale for the study is clearly linked to the mechanism of gotistobart, and limitations of prior work are acknowledged.

Evidence

paraphrase[Introduction, paragraph 1-3]

“The introduction describes the poor prognosis of sqNSCLC, the limited efficacy of docetaxel, and the mechanism and prior phase 1/2 data of gotistobart.”

paraphrase[Introduction, paragraph 3]

“The paper explains that gotistobart's pH-sensitive design may improve efficacy and reduce toxicity compared to other anti-CTLA-4 antibodies, leading to the hypothesis that it could benefit patients with PD-(L)1-resistant sqNSCLC.”

paraphrase[Discussion, last three paragraphs]

“The discussion notes the exploratory nature of stage 1, overrepresentation of Asian patients, and the open-label design as limitations.”

The paper describes randomization using an Interactive Web Response System with stratification factors. The open-label design is stated, but no rationale for the lack of blinding is provided. The stage 1 is explicitly described as 'nonpivotal' and 'exploratory' and 'was not powered to demonstrate efficacy', so a formal power analysis is not applicable. Inclusion/exclusion criteria are detailed. The comparator arm (docetaxel) is an active control. No independent replication is reported as this is a single trial.

Sub-criteria

controlsADEQUATE

power analysisN/A

blinding levelsINADEQUATE

outlier handlingNOT REPORTED

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 85% conf

The study design is a randomized, open-label, active-controlled phase 3 trial. While randomization and stratification are described, the open-label design and lack of blinding for investigator-assessed endpoints are limitations. The stage 1 is explicitly exploratory and not powered for efficacy.

Evidence

direct quote[Methods, Randomization and stratification factors]

“Eligible patients were randomized using the Interactive Web Response System to receive gotistobart or docetaxel treatment stratified by factors that could impact prognosis: histology (squamous versus nonsquamous (stage 1 only)), presence of brain metastases (yes or no), ECOG PS score (0 versus 1) and region (USA and ex-USA).”

direct quote[Methods, Study design and patients]

“PRESERVE-003 ... is a two-stage (nonpivotal stage 1A and 1B, pivotal stage 2), randomized, open-label, active-controlled phase 3 trial”

direct quote[Results, Patient disposition]

“Stage 1 is exploratory and was not powered to demonstrate efficacy.”

WARNReviewer 2· 85% conf

The study design is described but lacks critical details on randomization method, blinding rationale, power analysis, and outlier/missing data handling, leading to a warning.

Evidence

direct quote[Methods, Randomization and stratification factors]

“Eligible patients were randomized using the Interactive Web Response System to receive gotistobart or docetaxel treatment stratified by factors...”

direct quote[Methods, Study design and patients]

“PRESERVE-003 is a two-stage, randomized, open-label, active-controlled phase 3 trial”

paraphrase[Methods, Statistical analysis]

“The paper states that stage 1 is exploratory and not powered, but no formal power calculation is provided.”

PASSReviewer 3· 92% conf

The study design is rigorously described for a nonpivotal stage of a phase 3 trial. Randomization, stratification, blinding (open-label with rationale), inclusion/exclusion criteria, and statistical methods are clearly reported. The exploratory nature and lack of formal power calculation are transparently stated.

Evidence

direct quote[Methods, Randomization and stratification factors]

direct quote[Discussion, paragraph 11]

“The use of investigator assessment rather than blinded, independent central reviewer assessment of PFS and ORR may be limited by the open-label design.”

direct quote[Introduction, last sentence]

“Stage 1 is exploratory and was not powered to demonstrate efficacy.”

The paper provides a detailed baseline demographics table (Table 1) including age, sex, race, region, ECOG PS, smoking status, and disease characteristics. Both sexes are included, so a justification for sex is not required. Age and health status (ECOG PS) are reported. Species/strain/source and housing conditions are not applicable for a human clinical trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper reports key biological variables for the human study population, including age, sex, race, ECOG PS, smoking status, and disease characteristics. Sex is reported but not justified as both sexes are included.

Evidence

direct quote[Table 1]

“Median age (range) in years | 64.0 (39–86) | 68.5 (43–84) | Sex, no. (%) | Male | 36 (80.0) | 38 (90.5) | Female | 9 (20.0) | 4 (9.5)”

direct quote[Table 1]

“Sex, no. (%) | Male | 36 (80.0) | 38 (90.5) | Female | 9 (20.0) | 4 (9.5)”

PASSReviewer 2· 80% conf

Sex and demographics are reported in detail, but weight is missing from the age/weight/health assessment, making the age_weight_health criterion inadequate but overall still passing.

Evidence

direct quote[Results, Table 1]

“Sex, no. (%) | Male | 36 (80.0) | 38 (90.5) | | Female | 9 (20.0) | 4 (9.5)”

direct quote[Results, Table 1]

“Median age (range) in years | 64.0 (39–86) | 68.5 (43–84)”

direct quote[Results, Table 1]

“Race, Region, ECOG PS, Smoking status, etc. are listed.”

PASSReviewer 3· 95% conf

Applicable biological variables for a human trial are reported: sex, age, ECOG performance status, race, region, smoking status, and baseline metastases. The study includes both sexes (80% male, 20% female in gotistobart arm) so a single-sex justification is not needed.

Evidence

direct quote[Table 1]

“Sex, no. (%) Male 36 (80.0) Female 9 (20.0) / Median age (range) in years 64.0 (39–86)”

direct quote[Table 1]

“Race, no. (%) Asian 32 (71.1) White 11 (24.4) Black or African American 2 (4.4) Other 0”

The ethics section states approval by the institutional review board/ethics committee and national regulatory authority, explicitly naming the central Western Institutional Review Board for the USA and independent review boards at each site elsewhere. Written informed consent was obtained. The study was conducted in accordance with the Declaration of Helsinki, CIOMS, and ICH-GCP. All criteria are adequately reported.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper provides a detailed ethics and consent statement, including named approving bodies, informed consent, and regulatory compliance.

Evidence

direct quote[Methods, Ethics approval and consent]

“The central Western Institutional Review Board provided approval in the USA. In Australia, China, Korea and the UK, the independent review boards or ethics committees at each study site provided approval.”

direct quote[Methods, Ethics approval and consent]

“All patients provided written informed consent before enrollment.”

direct quote[Methods, Ethics approval and consent]

“The study was conducted in accordance with local and national regulations, as well as consensus ethical principles derived from the Declaration of Helsinki, the Council for International Organizations of Medical Sciences International Ethical Guidelines and the International Council for Harmonisation Good Clinical Practice Guidelines.”

PASSReviewer 2· 95% conf

Ethical approvals are clearly reported with named IRB, informed consent, and regulatory compliance statements.

Evidence

direct quote[Methods, Ethics approval and consent]

“All patients provided written informed consent before enrollment.”

direct quote[Methods, Ethics approval and consent]

PASSReviewer 3· 98% conf

The study reports approval by named ethics committees (central Western IRB in USA and site-specific committees in other countries), written informed consent from all patients, and adherence to the Declaration of Helsinki, CIOMS, and ICH-GCP guidelines.

Evidence

direct quote[Methods, Ethics approval and consent]

“All patients provided written informed consent before enrollment.”

direct quote[Methods, Ethics approval and consent]

The paper identifies the investigational product gotistobart (BNT316/ONC-392) and the comparator docetaxel, with their dosing regimens. The statistical software SAS (version 9.4 or later) is identified. No antibodies, cell lines, or other biological resources are used in this clinical trial, so those sub-criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (gotistobart) and comparator (docetaxel) are identified with dosing regimens. Statistical software is identified. No other biological resources (antibodies, cell lines) are used.

Evidence

direct quote[Methods, Treatments]

“In stage 1A, gotistobart was administered at 3 mg kg −1 or 6 mg kg −1 (with two loading doses of 10 mg kg −1 ), and in stage 1B, gotistobart was administered at 6 mg kg −1 (with two loading doses of 10 mg kg −1 ). Docetaxel was dosed at 75 mg m − 2 .”

direct quote[Methods, Statistical analysis]

“Statistical analyses were conducted using SAS (version 9.4 or later).”

WARNReviewer 2· 85% conf

The investigational products are partially identified: gotistobart is named with manufacturer and dose, but docetaxel is not identified by manufacturer/source. Software is adequately identified.

Evidence

direct quote[Methods, Treatments]

“OncoC4 Inc. supplied gotistobart and oversaw trial execution and data collection.”

direct quote[Methods, Treatments]

“Docetaxel was dosed at 75 mg m − 2 .”

direct quote[Methods, Statistical analysis]

“Statistical analyses were conducted using SAS (version 9.4 or later).”

PASSReviewer 3· 90% conf

The investigational products (gotistobart and docetaxel) are named with dose/regimen, and the sponsor/source is stated for gotistabart. Custom software (SAS) is identified with version.

Evidence

direct quote[Abstract, Methods (Treatments)]

“gotistobart (6 mg kg −1 with two 10 mg kg −1 loading doses every 3 weeks)”

direct quote[Methods, Statistical analysis]

“Statistical analyses were conducted using SAS (version 9.4 or later).”

Tests include log-rank, Cox proportional-hazards, exact binomial for ORR. Exact p-value (0.0102) and HR with 95% CI are provided. Software is SAS 9.4. Data are presented with K-M curves and waterfall plots. Assumptions (e.g., proportional hazards) are not checked, but this is common in clinical trials. 6/7 sub-criteria are adequate, no demonstrable errors.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityPASS

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 85% conf

Statistical tests are named, and exact p-values are reported for the primary analysis. However, test assumptions are not verified, effect sizes with confidence intervals are reported, and data presentation is adequate for a clinical trial. The mathematical plausibility check is not applicable for these continuous survival data.

Evidence

direct quote[Results, Primary outcomes in patients with sqNSCLC]

“median OS was not reached (95% confidence interval (CI) 9.3 months to not evaluable (NE)) with gotistobart and 10.0 months (95% CI 6.2 to 11.9 months) with docetaxel (hazard ratio (HR) 0.46, 95% CI 0.25 to 0.84, two-sided P value = 0.0102).”

absence[Methods, Statistical analysis]

Test assumptions are not explicitly verified.

PASSReviewer 2· 90% conf

Statistical tests are named, exact p-values and effect sizes with CIs are reported, software is identified, and data presentation follows clinical trial standards. Assumptions are not explicitly verified, but the overall reporting is adequate.

Evidence

direct quote[Methods, Statistical analysis]

“OS curves were generated using Kaplan–Meier estimates. HRs and associated 95% CIs were calculated from a Cox proportional-hazards model.”

direct quote[Results, Primary outcomes]

“median OS was not reached (95% CI 9.3 months to not evaluable (NE)) with gotistobart and 10.0 months (95% CI 6.2 to 11.9 months) with docetaxel (HR 0.46, 95% CI 0.25 to 0.84, two-sided P value = 0.0102).”

direct quote[Results, Figures 2 and 3]

“Kaplan–Meier estimates of OS (a) and PFS (investigator assessment) (b) in patients with sqNSCLC.”

PASSReviewer 3· 85% conf

Statistical methods are well-described: Kaplan-Meier for OS/PFS, Cox proportional hazards for HR, log-rank test for p-value, exact binomial for ORR CI. Exact p-values and effect sizes with CIs are reported. Software is identified. The only minor gap is that assumptions for Cox model (proportional hazards) are not explicitly verified, but this is acceptable for a clinical trial using standard methods.

Evidence

direct quote[Methods, Statistical analysis]

“OS curves were generated using Kaplan–Meier estimates. HRs and associated 95% CIs were calculated from a Cox proportional-hazards model.”

direct quote[Results, Primary outcomes, Table 2]

“Nominal P value (two-sided log rank) 0.0102”

direct quote[Results, Primary outcomes]

“hazard ratio 0.46, 95% CI 0.25 to 0.84”

The data availability statement specifies that data will be made available to qualified researchers upon request within 12 months of study completion, with a contact email and data access agreement. This is reported_and_adequate for a clinical trial with identifiable patient data. Repository deposit and accession numbers are not applicable. Code sharing is not applicable as only commercial software was used.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 90% conf

A data availability statement is present, but it is vague ('available to qualified researchers upon request') with a mechanism described. No code sharing is mentioned. The trial is ongoing, so data are not yet deposited.

Evidence

direct quote[Data availability]

“Upon completion of this clinical trial, the data that support the findings of this study will be made available to qualified researchers. Proposals should be directed to pzheng@oncoc4.com. To gain access, data requestors will need to sign a data access agreement.”

PASSReviewer 2· 95% conf

A data availability statement is provided with a concrete route for access (email, data access agreement, timeframe). No other data or code repositories are applicable.

Evidence

direct quote[Data availability]

“Upon completion of this clinical trial, the data that support the findings of this study will be made available to qualified researchers. Proposals should be directed to pzheng@oncoc4.com.”

direct quote[Data availability]

“Data will be made available; to qualified researchers upon request, within 12 months of the study completion data and for a period of 2 years thereafter.”

PASSReviewer 3· 95% conf

A data availability statement is present with a managed access mechanism (qualified researchers, data access agreement, contact email). For this clinical trial, patient-level data cannot be publicly deposited, so the statement is adequate.

Evidence

direct quote[Data availability section]

Methods are comprehensive: randomization, stratification, eligibility, treatment, endpoints, statistical analysis. Trial registration (NCT05671510) is provided. The paper includes a reporting summary and references supplementary information. All outcomes (OS, PFS, ORR, DoR, safety) are reported; negative results for non-sqNSCLC and the low-dose arm are reported transparently. Limitations are discussed. Conclusions are appropriately cautious for a nonpivotal stage. Funding sources and competing interests are fully detailed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper provides a detailed methods section, trial registration, limitations discussion, proportional conclusions, and funding/COI statements. A reporting guideline is not explicitly referenced, but a reporting summary is linked.

Evidence

direct quote[Abstract]

“ClinicalTrials.gov identifier: NCT05671510”

direct quote[Discussion, paragraph 8]

“A limitation of the study is that the Asian patient population was overrepresented, and Hispanic and Black/African American patients were underrepresented in stage 1.”

direct quote[Methods, Reporting summary]

“Further information on research design is available in the linked to this article.”

PASSReviewer 2· 95% conf

The manuscript is well-reported with detailed methods, trial registration, reporting guideline reference, all outcomes reported, limitations discussed, proportional conclusions, and funding/COI disclosure.

Evidence

direct quote[Abstract, Methods]

“ClinicalTrials.gov identifier: NCT05671510 (https://clinicaltrials.gov/search?term=NCT05671510).”

direct quote[Discussion, paragraph 9]

“A limitation of the study is that the Asian patient population was overrepresented, and Hispanic and Black/African American patients were underrepresented in stage 1.”

direct quote[Competing interests, Acknowledgements]

“The PRESERVE-003 ( NCT05671510 ) study is sponsored by OncoC4 Inc. and conducted in collaboration with BioNTech.”

PASSReviewer 3· 97% conf

The manuscript is well-structured with detailed methods, clinical trial registration, reporting guideline adherence (Nature Portfolio reporting summary), transparent reporting of all pre-specified outcomes including negative results, discussion of limitations, proportional conclusions, and complete funding/COI statements.

Evidence

direct quote[Abstract, Methods]

“ClinicalTrials.gov identifier: NCT05671510”

direct quote[Discussion, paragraph 11]

“A limitation of the study is that the Asian patient population was overrepresented, and Hispanic and Black/African American patients were underrepresented in stage 1.”

paraphrase[Acknowledgements, Competing interests]

“Funding from OncoC4 and BioNTech is acknowledged; detailed COI statements for all authors are provided.”

4 copyedit issues flagged: mostly clarity, consistency.

Checked 35 references: 34 verified — 1 unresolved.

Reproducibility

2 data/code links checked; 2 live.

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Αlpha¹ Rigor Action ItemsFinal pass before journal submission

This is a post-publication audit. The published work is reasonably robust for an exploratory stage 1 report, but an informed reader should weigh the overstated conclusions (claims of 'transform the treatment paradigm' go beyond the nonpivotal evidence) and the incomplete reporting of the open-label design and comparator sourcing. A correction to temper the claims and add missing reporting details would strengthen the paper's credibility.

1.
HIGHreporting
Temper the claim in Abstract and Discussion that gotistobart may 'transform the treatment paradigm' to reflect that these are exploratory, nonpivotal stage 1 results requiring validation in the ongoing stage 2.
The claim audit flagged this as overstated; the evidence from 45 patients in a nonpowered stage does not support a transformative paradigm shift, and over-claiming could mislead readers and attract criticism.
2.
HIGHreporting
Add the manufacturer/source of docetaxel in the Methods (Treatments) section to fully identify the active comparator.
The key resources checklist requires source identification for all investigational products; the missing information for the comparator was flagged by a reviewer.
3.
HIGHrigor
Verify the NCCN Clinical Practice Guidelines reference (Non-Small Cell Lung Cancer Version 8) that was not found in any registry; correct the reference or replace it with a verifiable source.
A citation that cannot be located in Crossref/OpenAlex raises a possible fabrication signal and undermines the paper's reference integrity.
4.
HIGHstatistics
In the Statistical analysis section, add a statement about whether the proportional hazards assumption was tested for the Cox model (e.g., using Schoenfeld residuals) and the result, or acknowledge it as a limitation.
Two reviewers noted the absence of assumption verification; adding this strengthens the statistical reporting and is considered best practice.
5.
HIGHreporting
In the Discussion, expand the limitation regarding the open-label design to explicitly address the potential bias in investigator-assessed endpoints and explain why blinding was not feasible.
The open-label design was flagged by all reviewers as lacking a rationale; even though it is mentioned as a limitation, a clear explanation of why blinding was not used would improve transparency.
6.
MEDIUMstatistics
Describe the handling of missing data and outliers in the Statistical analysis section (e.g., censoring rules, no imputation, observed-data analysis).
The paper states analyses were based on observed data only, but does not formally describe missing data handling; adding this meets standard reporting criteria.
7.
MEDIUMreporting
Provide the number of OS events per treatment arm in the Results to allow readers to assess event distribution and median follow-up adequacy.
This information is standard for survival analyses and was suggested by a reviewer to improve data transparency.
8.
MEDIUMreporting
Add a CONSORT flow diagram specifically for the sqNSCLC subset, or ensure the existing Fig. 1 includes all patient disposition details for this subgroup.
A reviewer recommended improved transparency in patient flow; a CONSORT diagram is standard for RCTs and aids reproducibility.
9.
MEDIUMreporting
Explicitly name the reporting guideline (e.g., CONSORT) in the Methods or Reporting summary section rather than just linking a reporting summary.
One reviewer noted the guideline is not explicitly named; naming the guideline helps readers identify the reporting standards followed.
10.
LOWcopyedit
In the Abstract, ensure consistent capitalization of 'gotistobart' (use lowercase as in the main text, or capitalize consistently throughout).
The copyedit pass flagged this consistency issue; minor but improves professional presentation.
11.
LOWcopyedit
In Results (Patient disposition), change 'of which' to 'of whom' for grammatical correctness.
Minor grammatical correction flagged by copyedit; improves language quality.
12.
LOWcopyedit
In Methods (Statistical analysis), rephrase the sentence about efficacy analyses for grammatical agreement: 'Efficacy analyses were conducted... and were based on observed data' (subject-verb agreement).
Copyedit flagged the original 'and was based' as grammatically incorrect; this fix improves clarity.

Full text (55,589 chars)Analyzed: Jul 16, 2026

Read alongside